Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Down 8.5% – Here’s What Happened

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’s share price fell 8.5% during mid-day trading on Tuesday . The stock traded as low as $13.59 and last traded at $13.60. 160,285 shares changed hands during trading, a decline of 51% from the average session volume of 329,598 shares. The stock had previously closed at $14.87.

Analyst Upgrades and Downgrades

YMAB has been the topic of a number of research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, September 9th. Morgan Stanley lowered their target price on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a report on Tuesday, August 13th. Canaccord Genuity Group reissued a “buy” rating and set a $26.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Finally, Wedbush reiterated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Y-mAbs Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.14.

Y-mAbs Therapeutics Price Performance

The firm’s 50-day simple moving average is $14.12 and its 200 day simple moving average is $13.14. The firm has a market capitalization of $587.43 million, a price-to-earnings ratio of -24.70 and a beta of 0.68.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. The company had revenue of $18.46 million for the quarter, compared to the consensus estimate of $23.38 million. During the same quarter in the previous year, the business earned ($0.18) earnings per share. As a group, research analysts predict that Y-mAbs Therapeutics, Inc. will post -0.62 earnings per share for the current year.

Insider Transactions at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 30,000 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $12.97, for a total value of $389,100.00. Following the sale, the insider now owns 67,681 shares of the company’s stock, valued at $877,822.57. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, COO Joris Wilms sold 5,000 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the sale, the chief operating officer now directly owns 30,600 shares in the company, valued at $449,514. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Thomas Gad sold 30,000 shares of the stock in a transaction on Monday, September 16th. The stock was sold at an average price of $12.97, for a total transaction of $389,100.00. Following the sale, the insider now directly owns 67,681 shares in the company, valued at $877,822.57. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 100,000 shares of company stock valued at $1,338,100 in the last 90 days. 22.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Large investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. boosted its stake in shares of Y-mAbs Therapeutics by 9.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 279,577 shares of the company’s stock worth $3,676,000 after acquiring an additional 23,982 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Y-mAbs Therapeutics during the 3rd quarter worth about $133,000. Principal Financial Group Inc. acquired a new stake in Y-mAbs Therapeutics during the 3rd quarter worth approximately $267,000. Rice Hall James & Associates LLC increased its position in shares of Y-mAbs Therapeutics by 21.1% in the third quarter. Rice Hall James & Associates LLC now owns 108,684 shares of the company’s stock worth $1,429,000 after purchasing an additional 18,949 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Y-mAbs Therapeutics by 66.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock worth $113,000 after buying an additional 3,416 shares during the last quarter. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.